Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-227P is a **pseudogene copy** of the gene encoding U6 small nuclear RNA (snRNA), an RNA component essential for the spliceosome, which catalyzes the removal of introns from pre-mRNA in eukaryotes. While **U6 snRNA** itself is highly conserved and crucial for splicing, **RNU6-227P** represents a non-functional, processed copy (pseudogene) and is not believed to encode a functional product or participate in biological processes[1][5]. The presence of multiple U6-derived pseudogenes is common in vertebrate genomes due to the evolutionary importance of splicing, but individual pseudogenes like RNU6-227P are not considered therapeutic targets, are not associated with disease, and do not exhibit known regulatory or functional activity[1][5]. **Key points:** - This entity is a *pseudogene*, not an active snRNA or protein, and therefore is not a "target" in the sense of therapeutics or drug discovery. - There is no evidence of functional properties, roles in splicing, or disease association for RNU6-227P itself[1][5]. - If you are interested in the **functional snRNA active in the spliceosome**, the appropriate canonical name is "U6 small nuclear RNA" or "U6 snRNA", not this pseudogene[5]. **Notes on incorrectness:** - This entry is *not* an active gene, protein, or therapeutic target. - The target appears correctly named as a pseudogene, but using it as a drug target or functional molecular entity would be incorrect[1]. - If a functional snRNA is needed, reference the active "U6 small nuclear RNA" instead. Pseudogenes like RNU6-227P do not yield functional products or have known pharmacological relevance[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 227, pseudogene (RNU6-227P).